Phase 5 · Metabolic research

Cagrilintide vs Tirzepatide

Cagrilintide is an investigational amylin analogue, whereas tirzepatide is an approved dual-incretin medicine supported by a larger clinical program.

The short answer

Different does not automatically mean better.

Cagrilintide is an investigational amylin analogue, whereas tirzepatide is an approved dual-incretin medicine supported by a larger clinical program.

Side ACagrilintide

Side BTirzepatide

Side-by-side

What actually separates them

Compare

Cagrilintide

Tirzepatide

Identity

CagrilintideLong-acting amylin analogue.

TirzepatideDual GLP-1 and GIP receptor agonist.

Main biological pathway

CagrilintideInvestigated for amylin-related satiety and food-intake signaling.

TirzepatideCombines two incretin pathways affecting appetite and glucose regulation.

Human evidence

CagrilintidePhase 2 monotherapy data and study as a standalone arm and combination component.

TirzepatideMultiple large phase 3 programs across obesity and diabetes.

U.S. regulatory status

CagrilintideNot FDA approved as a standalone medicine as of July 20, 2026.

TirzepatideFDA-approved products have specific diabetes and weight-management indications.

Best-established context

CagrilintideInvestigational obesity research.

TirzepatideLabeled treatment of eligible patients.

Central uncertainty

CagrilintideLong-term standalone safety, efficacy and regulatory outcome.

TirzepatideWhich eligible patients obtain a favorable personal benefit-risk balance.

Evidence check

Known, unknown, and easy to misread

What is established

Both pathways can influence appetite and body weight, and both molecules have produced weight reduction in their respective trials.

What is not established

No completed randomized head-to-head trial has shown whether cagrilintide is more or less effective than tirzepatide.

How to read it

REDEFINE and SURMOUNT are separate trial programs. Differences in their headline results cannot be attributed only to the drugs.

Beginner bottom line

Cagrilintide is an investigational amylin analogue, whereas tirzepatide is an approved dual-incretin medicine supported by a larger clinical program.

Quick questions

Frequently asked questions

Do cagrilintide and tirzepatide activate the same receptors?

No. They use distinct amylin and incretin pathways.

Which has the stronger evidence base today?

Tirzepatide, because it has multiple completed phase 3 programs and approved uses.

Can results from REDEFINE 1 and SURMOUNT-1 determine a winner?

No. That would be an indirect comparison between different studies.

Check the evidence

Primary and official sources

Want to examine the evidence with the community?

Bring a study, ask a focused question, or compare interpretations in Research Discussions.

Visit Research Discussions